Endotronix, an Edwards Lifesciences company, announced positive one-year clinical results from its PROACTIVE-HF trial for the Cordella Pulmonary Artery (PA) Sensor System on September 28, 2024. The data revealed a 49% reduction in one-year heart failure hospitalization and all-cause mortality rate among patients managed with Cordella, with 36 events per 100 patients compared to a pre-specified 70 events per 100 patients.
The study, presented at the Heart Failure Society of America Annual Scientific Meeting, also demonstrated significant improvements in secondary endpoints. These included enhanced quality of life for patients and a reduction in biomarker levels, further validating the system's clinical benefits.
These consistent and compelling results reinforce that PA pressure-guided therapy improves heart failure outcomes. The comprehensive data from the Cordella system supports remote medical adjustments and increases patient engagement in their own care, positioning the technology for continued adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.